MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats

Yitao Liu, Ludmila Belayev, Weizhao Zhao, Raul Busto, Myron Ginsberg

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the effects of MRZ 2/579, an uncompetitive N-methyl-D-aspartate antagonist, on infarct size, extent of swelling and neurological deficit in a model of transient middle cerebral artery occlusion in rats. Physiologically controlled Sprague-Dawley rats received 2 h MCAo by retrograde insertion of an intraluminal suture coated with poly-L-lysine. The agent (MRZ 2/579) or vehicle (sodium chloride 0.9%) was administered i.v. immediately after suture removal following a 2-h period of MCAo. Two experimental groups were studied: group A was treated by vehicle (bolus infusion:1 ml/kg for 10 min followed by infusion of 6 ml/kg/h over 6 h). Group B was treated by MRZ 2/579 (bolus infusion:10 mg/kg for 10 min followed by infusion of 6 mg/kg/h over 6 h). The neurological status was evaluated during occlusion (at 60 min) and daily for 3 days after MCAo. Brains were then perfusion-fixed, and infarct volumes and brain swelling were determined. MRZ 2/579 significantly improved the neurological score compared to vehicle-treated rats at 48 h (6.2±0.6 and 8.7±0.5, respectively; P<0.004) and 72 h after MCAo (5.2±0.6 and 8.4±0.5, respectively; P<0.001). Treatment with MRZ 2/579 also significantly reduced total infarct volume (29.3±11.1 and 83.2±16.5 mm3, respectively; P<0.01), cortical infarct volume (24.8±11.2 and 70.0±18.0 mm3, respectively; P<0.04) and subcortical infarction (21.2±4.1 and 49.6±4.5 mm3, respectively; P<0.0002). Brain swelling was also markedly reduced compared with vehicle-treated rats (4.7±1.3 and 10.8±2.1%, respectively; P<0.02). These results demonstrate that treatment with MRZ 2/579, when administered promptly after reperfusion, confers neuroprotective effects on infarct volume, brain swelling, and neurological score compared to the vehicle group. Themes: Disorders of the nervous system. Topics: Ischemia. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)111-119
Number of pages9
JournalBrain Research
Volume862
Issue number1-2
DOIs
StatePublished - Apr 17 2000

Fingerprint

Brain Edema
N-Methylaspartate
Brain Ischemia
Sutures
Middle Cerebral Artery Infarction
Cerebral Infarction
Neuroprotective Agents
Nervous System Diseases
Sodium Chloride
Lysine
Reperfusion
Sprague Dawley Rats
neramexane
Ischemia
Perfusion
Brain

Keywords

  • Focal cerebral ischemia
  • Image-analysis
  • MRZ 2/579
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

@article{8437ed865703434a9ddeea5210e6041e,
title = "MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats",
abstract = "The purpose of this study was to evaluate the effects of MRZ 2/579, an uncompetitive N-methyl-D-aspartate antagonist, on infarct size, extent of swelling and neurological deficit in a model of transient middle cerebral artery occlusion in rats. Physiologically controlled Sprague-Dawley rats received 2 h MCAo by retrograde insertion of an intraluminal suture coated with poly-L-lysine. The agent (MRZ 2/579) or vehicle (sodium chloride 0.9{\%}) was administered i.v. immediately after suture removal following a 2-h period of MCAo. Two experimental groups were studied: group A was treated by vehicle (bolus infusion:1 ml/kg for 10 min followed by infusion of 6 ml/kg/h over 6 h). Group B was treated by MRZ 2/579 (bolus infusion:10 mg/kg for 10 min followed by infusion of 6 mg/kg/h over 6 h). The neurological status was evaluated during occlusion (at 60 min) and daily for 3 days after MCAo. Brains were then perfusion-fixed, and infarct volumes and brain swelling were determined. MRZ 2/579 significantly improved the neurological score compared to vehicle-treated rats at 48 h (6.2±0.6 and 8.7±0.5, respectively; P<0.004) and 72 h after MCAo (5.2±0.6 and 8.4±0.5, respectively; P<0.001). Treatment with MRZ 2/579 also significantly reduced total infarct volume (29.3±11.1 and 83.2±16.5 mm3, respectively; P<0.01), cortical infarct volume (24.8±11.2 and 70.0±18.0 mm3, respectively; P<0.04) and subcortical infarction (21.2±4.1 and 49.6±4.5 mm3, respectively; P<0.0002). Brain swelling was also markedly reduced compared with vehicle-treated rats (4.7±1.3 and 10.8±2.1{\%}, respectively; P<0.02). These results demonstrate that treatment with MRZ 2/579, when administered promptly after reperfusion, confers neuroprotective effects on infarct volume, brain swelling, and neurological score compared to the vehicle group. Themes: Disorders of the nervous system. Topics: Ischemia. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Focal cerebral ischemia, Image-analysis, MRZ 2/579, Neuroprotection",
author = "Yitao Liu and Ludmila Belayev and Weizhao Zhao and Raul Busto and Myron Ginsberg",
year = "2000",
month = "4",
day = "17",
doi = "10.1016/S0006-8993(00)02078-3",
language = "English",
volume = "862",
pages = "111--119",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats

AU - Liu, Yitao

AU - Belayev, Ludmila

AU - Zhao, Weizhao

AU - Busto, Raul

AU - Ginsberg, Myron

PY - 2000/4/17

Y1 - 2000/4/17

N2 - The purpose of this study was to evaluate the effects of MRZ 2/579, an uncompetitive N-methyl-D-aspartate antagonist, on infarct size, extent of swelling and neurological deficit in a model of transient middle cerebral artery occlusion in rats. Physiologically controlled Sprague-Dawley rats received 2 h MCAo by retrograde insertion of an intraluminal suture coated with poly-L-lysine. The agent (MRZ 2/579) or vehicle (sodium chloride 0.9%) was administered i.v. immediately after suture removal following a 2-h period of MCAo. Two experimental groups were studied: group A was treated by vehicle (bolus infusion:1 ml/kg for 10 min followed by infusion of 6 ml/kg/h over 6 h). Group B was treated by MRZ 2/579 (bolus infusion:10 mg/kg for 10 min followed by infusion of 6 mg/kg/h over 6 h). The neurological status was evaluated during occlusion (at 60 min) and daily for 3 days after MCAo. Brains were then perfusion-fixed, and infarct volumes and brain swelling were determined. MRZ 2/579 significantly improved the neurological score compared to vehicle-treated rats at 48 h (6.2±0.6 and 8.7±0.5, respectively; P<0.004) and 72 h after MCAo (5.2±0.6 and 8.4±0.5, respectively; P<0.001). Treatment with MRZ 2/579 also significantly reduced total infarct volume (29.3±11.1 and 83.2±16.5 mm3, respectively; P<0.01), cortical infarct volume (24.8±11.2 and 70.0±18.0 mm3, respectively; P<0.04) and subcortical infarction (21.2±4.1 and 49.6±4.5 mm3, respectively; P<0.0002). Brain swelling was also markedly reduced compared with vehicle-treated rats (4.7±1.3 and 10.8±2.1%, respectively; P<0.02). These results demonstrate that treatment with MRZ 2/579, when administered promptly after reperfusion, confers neuroprotective effects on infarct volume, brain swelling, and neurological score compared to the vehicle group. Themes: Disorders of the nervous system. Topics: Ischemia. Copyright (C) 2000 Elsevier Science B.V.

AB - The purpose of this study was to evaluate the effects of MRZ 2/579, an uncompetitive N-methyl-D-aspartate antagonist, on infarct size, extent of swelling and neurological deficit in a model of transient middle cerebral artery occlusion in rats. Physiologically controlled Sprague-Dawley rats received 2 h MCAo by retrograde insertion of an intraluminal suture coated with poly-L-lysine. The agent (MRZ 2/579) or vehicle (sodium chloride 0.9%) was administered i.v. immediately after suture removal following a 2-h period of MCAo. Two experimental groups were studied: group A was treated by vehicle (bolus infusion:1 ml/kg for 10 min followed by infusion of 6 ml/kg/h over 6 h). Group B was treated by MRZ 2/579 (bolus infusion:10 mg/kg for 10 min followed by infusion of 6 mg/kg/h over 6 h). The neurological status was evaluated during occlusion (at 60 min) and daily for 3 days after MCAo. Brains were then perfusion-fixed, and infarct volumes and brain swelling were determined. MRZ 2/579 significantly improved the neurological score compared to vehicle-treated rats at 48 h (6.2±0.6 and 8.7±0.5, respectively; P<0.004) and 72 h after MCAo (5.2±0.6 and 8.4±0.5, respectively; P<0.001). Treatment with MRZ 2/579 also significantly reduced total infarct volume (29.3±11.1 and 83.2±16.5 mm3, respectively; P<0.01), cortical infarct volume (24.8±11.2 and 70.0±18.0 mm3, respectively; P<0.04) and subcortical infarction (21.2±4.1 and 49.6±4.5 mm3, respectively; P<0.0002). Brain swelling was also markedly reduced compared with vehicle-treated rats (4.7±1.3 and 10.8±2.1%, respectively; P<0.02). These results demonstrate that treatment with MRZ 2/579, when administered promptly after reperfusion, confers neuroprotective effects on infarct volume, brain swelling, and neurological score compared to the vehicle group. Themes: Disorders of the nervous system. Topics: Ischemia. Copyright (C) 2000 Elsevier Science B.V.

KW - Focal cerebral ischemia

KW - Image-analysis

KW - MRZ 2/579

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=0034678533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034678533&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(00)02078-3

DO - 10.1016/S0006-8993(00)02078-3

M3 - Article

C2 - 10799675

AN - SCOPUS:0034678533

VL - 862

SP - 111

EP - 119

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -